GlaxoSmithKline Declines as FDA Clears Path for Advair Rivals, $8 Billion in Revenue Threatened

Published: Sep 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlaxoSmithKline Plc (GSK) fell the most in 20 months after U.S. regulators proposed a simpler route for rivals seeking to copy the company’s Advair respiratory drug, threatening almost $8 billion in revenue.

Help employers find you! Check out all the jobs and post your resume.

Back to news